BioCryst Pharmaceuticals Files Proxy Materials
Ticker: BCRX · Form: DEFA14A · Filed: Apr 24, 2025 · CIK: 882796
Sentiment: neutral
Topics: proxy-filing, regulatory
TL;DR
BioCryst filed proxy docs, no fee. Standard corporate stuff.
AI Summary
BioCryst Pharmaceuticals, Inc. filed a Definitive Additional Materials (DEFA14A) on April 24, 2025. This filing is related to their proxy statement and indicates that no fee was required for this submission. The company is based in Durham, NC, and operates in the biological products sector.
Why It Matters
This filing is a routine regulatory submission for BioCryst Pharmaceuticals, Inc., providing updated proxy materials to shareholders. It does not contain new financial results or strategic announcements but is part of the ongoing corporate governance process.
Risk Assessment
Risk Level: low — This filing is a routine DEFA14A, which typically contains proxy materials and does not represent a significant change in the company's financial or operational status.
Key Players & Entities
- BIOCRYST PHARMACEUTICALS INC (company) — Registrant
- 0001140361-25-015459 (filing_id) — Accession Number
- 20250424 (date) — Filing Date
- 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 (address) — Company Business Address
FAQ
What type of filing is this DEFA14A for BioCryst Pharmaceuticals, Inc.?
This filing is classified as Definitive Additional Materials (DEFA14A).
When was this DEFA14A filing submitted to the SEC?
The filing was submitted on April 24, 2025.
What is the primary business of BioCryst Pharmaceuticals, Inc. according to the filing?
BioCryst Pharmaceuticals, Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
Does this filing require a fee payment?
No, the filing indicates that no fee is required.
Where is BioCryst Pharmaceuticals, Inc. located?
The company's business and mailing address is 4505 Emperor Boulevard, Suite 200, Durham, NC 27703.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 24, 2025 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).